Fidelity Fidelity SPDR Advertisement
Home > Boards > US OTC > Medical - Drugs > Elite Pharmaceuticals (ELTP)

Products under development including a OXYCOTIN generic

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
TecNasty Member Profile
 
Followed By 221
Posts 5,375
Boards Moderated 3
Alias Born 09/28/07
160x600 placeholder
Quarterly Report (10-q) "Edgar (US Regulatory)" - 8/14/2014 4:07:25 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 8/12/2014 1:29:59 PM
Securities Registration: Employee Benefit Plan (s-8) "Edgar (US Regulatory)" - 7/29/2014 2:36:28 PM
Notice of Effectiveness (effect) "Edgar (US Regulatory)" - 7/9/2014 5:59:42 AM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) "Edgar (US Regulatory)" - 7/8/2014 5:16:17 PM
Post-effective Amendment to Registration Statement (pos Am) "Edgar (US Regulatory)" - 7/1/2014 10:13:11 AM
Annual Report (10-k) "Edgar (US Regulatory)" - 6/30/2014 1:55:58 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 6/23/2014 3:29:48 PM
Amended Statement of Changes in Beneficial Ownership (4/a) "Edgar (US Regulatory)" - 6/23/2014 3:14:17 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 6/18/2014 5:59:40 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 6/11/2014 6:02:41 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 5/23/2014 12:46:59 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 5/13/2014 6:49:30 PM
Notice of Effectiveness (effect) "Edgar (US Regulatory)" - 5/2/2014 6:01:02 AM
Securities Registration Statement (s-1/a) "Edgar (US Regulatory)" - 4/28/2014 4:35:55 PM
Confidential Treatment Order (ct Order) "Edgar (US Regulatory)" - 4/28/2014 1:36:44 PM
Amended Quarterly Report (10-q/a) "Edgar (US Regulatory)" - 4/25/2014 2:43:05 PM
Small Company Offering and Sale of Securities Without Registration (d) "Edgar (US Regulatory)" - 4/15/2014 1:40:11 PM
Securities Registration Statement (simplified Form) (s-3) "Edgar (US Regulatory)" - 4/15/2014 8:01:37 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 4/14/2014 8:01:13 AM
Proxy Statement (definitive) (def 14a) "Edgar (US Regulatory)" - 4/3/2014 4:06:43 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 3/18/2014 5:45:41 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 3/18/2014 5:39:00 PM
Annual Statement of Changes in Beneficial Ownership (5) "Edgar (US Regulatory)" - 3/18/2014 5:29:42 PM
Amended Statement of Beneficial Ownership (3/a) "Edgar (US Regulatory)" - 3/18/2014 5:18:03 PM
TecNasty   Friday, 03/04/11 11:13:27 AM
Re: None
Post # of 124503 
Products under development including a OXYCOTIN generic

Products Under Development
It is our general policy not to disclose products in our development pipeline or the status of such products until a product reaches a stage that we determine, for competitive reasons, in our discretion, to be appropriate for disclosure and because the disclosure of such information might suggest the occurrence of future matters or events that may not occur.

ELI-154 and ELI-216
For ELI-154, Elite has developed a once-daily oxycodone formulation using its proprietary technology. An investigational new drug application, or IND, has been filed and Elite has completed two pharmacokinetic studies in healthy subjects that compared blood levels of oxycodone from dosing ELI-154 and the twice-a-day product that is on the market currently, OxyContin® marketed in the U.S. by Purdue Pharma LP. These studies confirmed that ELI-154, when compared to twice-daily delivery, demonstrated an equivalent onset, more constant blood levels of the drug over the 24 hour period and equivalent blood levels to the twice-a-day product at the end of 24 hours. Elite has successfully manufactured multiple batches on commercial scale equipment and we have discussions ongoing in Europe for this product. We are looking for a partner who can complete the clinical studies required for Europe and who can sell and distribute the product in key European territories.

3

ELI-216 utilizes our patent-pending abuse-deterrent technology that is based on a pharmacological approach. ELI-216 is a combination of a narcotic agonist, oxycodone hydrochloride, in a sustained-release formulation intended for use in patients with moderate to severe chronic pain, and an antagonist, naltrexone hydrochloride, formulated to deter abuse of the drug. Both of these compounds, oxycodone hydrochloride and naltrexone hydrochloride, have been on the market for a number of years and sold separately in various dose strengths. Elite has filed an IND for the product and has tested the product in a series of pharmacokinetic studies. In single-dose studies for ELI-216, it was demonstrated that no quantifiable blood levels of naltrexone hydrochloride were released at a limit of quantification (“ LOQ” ) of 7.5 pg/ml. As described below, when crushed, naltrexone hydrochloride was released at levels that would be expected to eliminate the euphoria from the crushed oxycodone hydrochloride. This data is consistent with the premise of Elite’s abuse resistant technology, or ART, that essentially no naltrexone is released and absorbed when administered as intended. Products utilizing the pharmacological approach to deter abuse such as Suboxone®, a product marketed in the United States by Reckitt Benckiser Pharmaceuticals, Inc., and Embeda®, a product marketed in the United States by King Pharmaceuticals, have been approved by the FDA and are being marketed in the United States.

ELI-216 demonstrates a euphoria-blocking effect when the product is crushed. A study completed in 2007 was designed to determine the optimal ratio of oxycodone hydrochloride and the opioid antagonist, naltrexone hydrochloride, to significantly block the euphoric effect of the opioid if the product is abused by physically altering it (i.e., crushing). The study also helped determine the appropriate levels of naltrexone hydrochloride required to reduce or eliminate the euphoria experienced by subjects who might take crushed product to achieve a “high”.

Elite met with the FDA for a Type C clinical guidance meeting regarding the NDA development program for ELI-216. Elite has incorporated the FDA’s guidance into its developmental plan. Elite has obtained a special protocol assessment, or SPA, with the FDA for the ELI-216 Phase III protocol. Elite will conduct additional Phase I studies including, but not limited to, food effect, ascending dose and multi-dose studies.

Elite has developed ELI-154 and ELI-216 and retains the rights to these products. Elite has currently chosen to develop these products itself but expects to license these products at a later date to a third party who could provide funding for the remaining clinical studies, including a Phase III study, and who could provide sales and distribution for the product. The drug delivery technology underlying ELI-154 was originally developed under a joint venture with Elan which terminated in 2002.

According to the Elan Termination Agreement, Elite acquired all proprietary, development and commercial rights for the worldwide markets for the products developed by the joint venture, including ELI-154. Upon licensing or commercialization of ELI-154, Elite will pay a royalty to Elan pursuant to the Termination Agreement. If Elite were to sell the product itself, Elite will pay a 1% royalty to Elan based on the product’s net sales, and if Elite enters into an agreement with another party to sell the product, Elite will pay a 9% royalty to Elan based on Elite’s net revenues from this product. (Elite’s net product revenues would include license fees, royalties, manufacturing profits and milestones) Elite is allowed to recoup all development costs including research, process development, analytical development, clinical development and regulatory costs before payment of any royalties to Elan.


All my posts are my opinion Do your own DD before you invest. Dont invest unless you can afford to lose your entire investment.
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist